Skip Navigation

Sanofi CEO: Alnylam deal extension of Genzyme philosophy

Sanofi CEO: Alnylam deal extension of Genzyme philosophy

Chris Viehbacher, Sanofi CEO, discusses the $700 million deal Sanofi struck with Alnylam and the company's growth into the treatment of genetic diseases.

04:10

Mon, Jan 13 201410:10 AM EST

Earnings will make new record highs over the next few quarters, says Ed Yardeni

Earnings will make new record highs over the next few quarters, says Ed Yardeni

Charles Schwab's Kevin Gordon: More weakness in the labor market needs to happen for a Fed cut

Charles Schwab's Kevin Gordon: More weakness in the labor market needs to happen for a Fed cut

Google's fate hinges on this man: Demis Hassabis

Google's fate hinges on this man: Demis Hassabis

Austin Ekeler on joining the Washington Commanders

Austin Ekeler on joining the Washington Commanders

The Fed on rate cut timeline, restrictive monetary policy and inflation target

The Fed on rate cut timeline, restrictive monetary policy and inflation target

Earnings will make new record highs over the next few quarters, says Ed Yardeni

Earnings will make new record highs over the next few quarters, says Ed Yardeni

Charles Schwab's Kevin Gordon: More weakness in the labor market needs to happen for a Fed cut

Charles Schwab's Kevin Gordon: More weakness in the labor market needs to happen for a Fed cut

Google's fate hinges on this man: Demis Hassabis

Google's fate hinges on this man: Demis Hassabis

Austin Ekeler on joining the Washington Commanders

Austin Ekeler on joining the Washington Commanders

The Fed on rate cut timeline, restrictive monetary policy and inflation target

The Fed on rate cut timeline, restrictive monetary policy and inflation target